Hims & Hers unlocks access to injectable
GLP-1 medications, expanding its holistic weight loss program
focused on personalized and affordable solutions; prices start as
low as $199 a month
Hims & Hers Health, Inc., the leading health and wellness
platform, today announced the addition of GLP-1 injections to its
comprehensive weight loss portfolio, giving customers an affordable
way to consistently access safe, high-quality weight loss
treatment.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240520817107/en/
Hims & Hers unlocks access to
injectable GLP-1 medications, expanding its holistic weight loss
program focused on personalized and affordable solutions; prices
start as low as $199 a month. (Photo: Business Wire)
The company now offers access to GLP-1 injections in addition to
weight management oral medication kits, so that customers can truly
personalize their weight loss experience. Providing access to
compounded GLP-1s means eligible customers can use medications with
the same active ingredient as Ozempic® and Wegovy® without
navigating the shortages and costs that are currently limiting
access to the branded medications. Through a partnership with a
leading US manufacturer of generic and 503B compounded injectable
medications, Hims & Hers can help millions of Americans who
have obesity and are looking for help safely managing their
weight.
“The core of our business is to offer a truly personalized
experience that customers can trust and rely on,” said Andrew
Dudum, CEO and co-founder of Hims & Hers. “We’ve leveraged our
size and scale to secure access to one of the highest-quality
supplies of compounded GLP-1 injections available today. We’re
passing that access and value along to our customers, who deserve
the highest standard of clinical safety and efficacy to meet their
goals, and we're doing it in a safe, affordable way that others
can’t deliver."
According to the US Food and Drug Administration (FDA), around
70% of American adults have obesity or are overweight, and losing 5
to 10% of that body weight can reduce weight-related health risks,
such as diabetes and cardiovascular disease. GLP-1 medications can
support healthy weight loss along with a reduced calorie diet and
increased exercise by helping manage blood sugar levels, curb
cravings and suppress appetite, so people eat less without feeling
deprived.
The Hims & Hers platform is built on the belief that there
is no one-size-fits-all approach to health and wellness treatments.
Medical providers need a broad spectrum of solutions to address the
needs of customers and that includes those with weight challenges.
The current Hims & Hers Weight Loss offering is tracking to
eclipse $100M in revenue by the end of 20251, as previously
discussed, growing faster than any speciality in the company’s
history. Building on that success, offering access to compounded
GLP-1s gives medical providers and customers consistent and
affordable access to effective, trusted and safe medications.
“We know weight loss medications alone do not treat obesity
effectively, so we’ve built a holistic weight management solution
that supports customers as they combine powerful medications with
healthy lifestyle habits, such as exercise, improved sleep, and
eating nutritious foods,” said Dr. Patrick Carroll, Chief Medical
Officer of Hims & Hers. “Our comprehensive approach to weight
loss comes with support from medical providers who understand the
nuance of weight gain and weight loss. We design all of our
solutions to help customers be successful in the long term, and
that means providing an experience personalized to the
individual.”
GLP-1 injections are fulfilled and shipped from Hims & Hers'
affiliated pharmacies. Once consistent supply is available through
the pharmacies' wholesaler, Hims & Hers plans to make branded
options available to customers, expanding the offering beyond the
current oral medication kits and compounded GLP-1 injectable
medications.
For more information, visit https://www.forhers.com/weight-loss
or https://www.hims.com/weight-loss.
Pricing & Availability
- Pricing for weight loss medications starts as low as $79/month
for oral medication kits and $199/month for compounded GLP-1
injections. Pricing includes unlimited medical consultations with a
licensed provider.
- Medications are prescribed based on what medical providers
determine is medically appropriate and necessary for each
patient.
- Oral medication kits and compounded GLP-1 injections are not
available in all states.
About Hims & Hers Health, Inc.
Hims & Hers is the leading health and wellness platform on a
mission to help the world feel great through the power of better
health. We believe how you feel in your body and mind transforms
how you show up in life. That’s why we’re building a future where
nothing stands in the way of harnessing this power. Hims & Hers
normalizes health & wellness challenges—and innovates on their
solutions—to make feeling happy and healthy easy to achieve. No two
people are the same, so the company provides access to personalized
care designed for results. For more information, please visit
www.hims.com and www.forhers.com.
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements can be identified by the
use of forward-looking terminology, including the words “believe,”
“estimate,” “anticipate,” “expect,” “assume,” “imply,” “intend,”
“plan,” “may,” “will,” “potential,” “project,” “predict,”
“continue,” “could,” “confident,” “confidence,” or “should,” or, in
each case, their plural, their negative or other variations or
comparable terminology. There can be no assurance that actual
results will not materially differ from expectations. Such
statements include, but are not limited to, any statements relating
to our financial outlook and guidance, including our mission to
drive top-line growth and profitability and our ability to attain
our medium- and long-term financial targets; our expected future
financial and business performance, including with respect to the
Hims & Hers platform, our marketing campaigns, investments in
innovation, and our infrastructure, and the underlying assumptions
with respect to the foregoing; statements relating to events and
trends relevant to us, including with respect to our financial
condition, results of operations, short- and long-term business
operations, objectives, and financial needs; expectations regarding
our mobile applications, market acceptance, user experience,
customer retention, brand development, our ability to invest and
generate a return on any such investment, customer acquisition
costs, operating efficiencies and leverage (including our
fulfillment capabilities), the effect of any pricing decisions,
changes in our product or offering mix, the timing and market
acceptance of any new products or offerings, the success of our
business model, our market opportunity, our ability to scale our
business, the growth of certain of our specialties, our ability to
innovate on and expand the scope of our offerings and experiences,
our ability to reinvest into the customer experience, and our
ability to comply with the extensive, complex and evolving
regulatory requirements applicable to our business, including
without limitation state and federal healthcare, privacy and
consumer protection laws and regulations. These statements are
based on management’s current expectations, but actual results may
differ materially due to various factors.
The forward-looking statements contained in this press release
are based on our current expectations and beliefs concerning future
developments and their potential effects on us. Future developments
affecting us may not be those that we have anticipated. These
forward-looking statements involve a number of risks, uncertainties
(some of which are beyond our control) and other assumptions that
may cause actual results or performance to be materially different
from those expressed or implied by these forward-looking
statements. These risks and uncertainties include, but are not
limited to, those factors described in the “Risk Factors” section
of each of our most recently filed Quarterly Report on Form 10-Q,
our most recently filed Annual Report on Form 10-K, and any of our
subsequent filings with the Securities and Exchange Commission (the
“Commission”).
Should one or more of these risks or uncertainties materialize,
or should any of our assumptions prove incorrect, actual results
may vary in material respects from those projected in these
forward-looking statements. We undertake no obligation (and
expressly disclaim any obligation) to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as may be required under
applicable securities laws. These risks and others described in the
“Risk Factors” section of each of our most recently filed Quarterly
Report on Form 10-Q, our most recently filed Annual Report on Form
10-K, and any of our subsequent filings with the Commission may not
be exhaustive.
By their nature, forward-looking statements involve risks and
uncertainties because they relate to events and depend on
circumstances that may or may not occur in the future. We caution
you that forward-looking statements are not guarantees of future
performance and that our actual results of operations, financial
condition and liquidity, and developments in the industry in which
we operate may differ materially from those made in or suggested by
the forward-looking statements contained in reports we have filed
or will file with the Commission, including our most recently filed
Annual Report on Form 10-K, our most recently filed Quarterly
Report on Form 10-Q, and any of our subsequent filings with the
Commission. In addition, even if our results of operations,
financial condition and liquidity, and developments in the industry
in which we operate are consistent with the forward-looking
statements contained in such reports, those results or developments
may not be indicative of results or developments in subsequent
periods.
_________________________
1 Current guidance as of May 6 does not reflect the addition of
GLP-1 access on our platform and we are not updating guidance at
this time.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240520817107/en/
Jen Treadwell press@forhims.com
Hims and Hers Health (NYSE:HIMS)
Historical Stock Chart
From May 2024 to Jun 2024
Hims and Hers Health (NYSE:HIMS)
Historical Stock Chart
From Jun 2023 to Jun 2024